There was no major surprise surfacing in the Q3 report, but instead, it showed a lower cash burn than we had expected. The HEAL LL-37 proceeds according to the plans, and full patient recruitment is expected to be reached in early 2020. The company is in the middle of a preferential rights issue that could secure financing for at least an additional 12 months. The subscription price is set to SEK 3.71.